4-methoxy-1-methylcyclohexan-1-ol | 102878-81-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-methoxy-1-methylcyclohexan-1-ol
• 英文别名: 4-Methoxy-1-methyl-cyclohexanol
• CAS: 102878-81-9
• 化学式: C₈H₁₆O₂
• 分子量: 144.214
• InChiKey: XPIURESURDVXJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-甲氧基环己酮 、 甲基氯化镁 生成 4-methoxy-1-methylcyclohexan-1-ol
  参考文献：
  名称：

  CIANETTI, C.;MAIO, DI, G.;PIGNATELLI, V.;TAGLIATESTA, P.;VECCHI, E.;ZEULI+, TETRAHEDRON, 1983, 39, N 4, 657-666

  摘要：

  DOI：

文献信息

• MONOMERS, POLYMERS AND PHOTORESIST COMPOSITIONS
  申请人：Rohm and Haas Electronic Materials Korea Ltd.

  公开号：US20180203352A1

  公开（公告）日：2018-07-19

  Monomers and polymers are provided that comprise a carbon alicyclic group or heteroalicyclic group that comprises 1) one or more acid-labile ring substituents and 2) one or more ether or thioether ring substituents. Photoresists that comprise such polymers also are provided.

  提供了包含碳脂环基团或杂环脂环基团的单体和聚合物，其中包括1）一个或多个酸敏感的环取代基和2）一个或多个醚或硫醚环取代基。还提供了包含这种聚合物的光刻胶。
• 3-SUBSTITUTED-6-ARYL PYRIDINES
  申请人：Hutchinson Alan J.

  公开号：US20110281837A1

  公开（公告）日：2011-11-17

  3-substituted-6-aryl pyridines of Formula I are provided: wherein R 1 , R 2 , R 3 , R 8 , R 9 , A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.

  本发明提供了式I的3-取代-6-芳基吡啶化合物：其中R1、R2、R3、R8、R9、A和Ar的定义在此处。这些化合物是C5a受体的配体。式I的优选化合物具有高亲和力结合到C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的制药组合物，以及将这些化合物用于治疗各种炎症、心血管和免疫系统疾病的用途。此外，本发明提供了标记的3-取代-6-芳基吡啶，可用作C5a受体定位的探针。
• NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF
  申请人：Harvey Andrew John

  公开号：US20110166130A1

  公开（公告）日：2011-07-07

  The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.

  本发明涉及化合物，其在细胞中调节钾通道活性中具有用处，特别是调节T细胞中发现的Kv1.3通道的活性。本发明还涉及使用这些化合物治疗或预防自身免疫和炎症性疾病，包括多发性硬化症，含有这些化合物的制药组合物以及它们的制备方法。
• 3-Substituted-6-Aryl Pyridines
  申请人：Hutchison Alan J.

  公开号：US20090176980A1

  公开（公告）日：2009-07-09

  3-substituted-6-aryl pyridines of Formula I are provided: wherein R 1 , R 2 , R 3 , R 8 , R 9 , A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.

  本发明提供了式I中的3-取代-6-芳基吡啶化合物： 其中R1、R2、R3、R8、R9、A和Ar在此定义。这些化合物是C5a受体的配体。式I的优选化合物具有高亲和力结合C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的药物组合物，以及在治疗各种炎症，心血管和免疫系统疾病中使用这些化合物的用途。此外，本发明提供了标记的3-取代-6-芳基吡啶，可用作C5a受体的定位探针。
• Inhibitors of beta-secretase
  申请人：Vitae Pharmaceuticals, Inc.

  公开号：US10336717B2

  公开（公告）日：2019-07-02

  The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.

  本发明涉及一种由以下结构式表示的化合物 或其药学上可接受的盐。此外，还介绍了这些化合物的药物组合物和使用方法。